Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
-
Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the makers of Wegovy and Mounjaro are seeking FDA approval for tablets. -
Getting a diagnosis is key since there are different causes for the problem calling for different treatments. Here's what to know and how to find support if you are living with hair loss. -
Hormone therapy drugs have carried box warning labels for years. Food and Drug Administration Commissioner Marty Makary talks with NPR about why the agency is removing them. -
The Trump administration struck deals with pharmaceutical companies Novo Nordisk and Eli Lilly to lower prices and copays for type 2 diabetes and obesity drugs --- but not everyone will qualify.
-
Medicare beneficiaries will soon be able to get obesity and Type 2 diabetes drugs for a $50 copay. But there are some limitations. -
There are strict rules about what drug companies can say in TV or print ads. But a new study shows there's a lot more wiggle room when companies pay to sponsor online search results. -
The U.K.-based drugmaker became the second to strike a deal with the Trump administration as part of the president's push to rein in U.S. drug prices. -
President Trump on Tuesday announced a deal with Pfizer to sell its drugs directly to consumers at discounted prices. They'll be available through a website operated by the federal government.
-
The Trump administration says it is making deals with drug companies to lower prices U.S. consumers pay for medicines. But key details are missing on how the initiative would work. -
A law firm appealing a stalled case against Tylenol's maker, Kenvue, says people are calling to join the suit, alleging the painkiller caused autism in children whose mothers took it during pregnancy.
